PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number:	10/738,938
Filing Date:	December 17, 2003
First Named Inventor:	Raul G. Barletta
Group Art Unit:	1652
Examiner Name:	~~Allyson Purnell~~ RAMIREZ, DELIA
Attorney Docket Number:	801204-0003

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
DM		2003/0133952		Raul G. Barletta and Ofelia Barletta-Chacon	July 17, 2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
			None					

OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS AND INFORMATION

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
DM		BROWN, BARBARA A., et al., "*Mycobacterium wolinskyi* Sp. Nov. and *Mycobacterium goodii* Sp. Nov., Two New Rapidly Growing Species Related to *Mycobacterium smegmatis* and Associated with Human Would Infections: A Cooperative Study from the International Working Group on Mycobacterial Taxonomy", *International Journal of Systematic Bacteriology*. 1999, Vol. 49, p. 1493-1511.	
		HINGLEY-WILSON, SUZANNE M., et al., "Survival Perspectives from the World's Most Successful Pathogen, *Mycobacterium tuberculosis*", *Nature Immunology*. Oct. 2003, Vol. 4, No. 10, p. 949-955.	
		LAGIER, BEATRICE, et al., " Identification of Genetic Loci Implicated in the Survival of *Mycobacterium smegmatis* in Human Mononuclear Phagocytes", *Molecular Microbiology*. 1998, Vol. 29, No. 2, p. 465-475.	
		PIDDINGTON, DEBRA L., et al., "Cu,Zn Superoxide Dismutase of *Mycobacterium tuberculosis* Contributes to Survival in Activated Macrophages That Are Generating an Oxidative Burst", *Infection and Immunity*. Aug 2001, Vol. 69, No. 8, p. 4980-4987.	
DM		HARTH, GUNTER, et al., "High-Level Heterologous Expression and Secretion in Rapidly Growing Nonpathogenic Mycobacteria of Four Major Mycobacterium tuberculosis Extracellular Proteins Considered To Be Leading Vaccine Candidates and Drug Targets", *Infection and Immunity*,. June 1997, Vol. 65, No. 6, p. 2321-2328.	

Examiner Signature		Date Considered	10/11/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number:	10/738,938
Filing Date:	December 17, 2003
First Named Inventor:	Raul G. Barletta
Group Art Unit:	1652
Examiner Name:	~~Allyson Purnell~~ RAMIREZ, DELIA
Attorney Docket Number:	801204-0003

OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS AND INFORMATION			
JR		MacGOWAN, ALASDAIR, et al., "In Vitro Models, In Vivo Models, and Pharmacokinetics: What Can We Learn from In Vitro Models?", *CID*. 2001 Vol. 33 (Suppl 3), p. S214-S220.	
		ORME, IAN M. and Collins, Frank M., "Mouse Model of Tuberculosis". Chapter 8, p. 113-134. *Tuberculosis: Pathogenesis, Protection and Control*, Barry R. Bloom (ed.), 1994, American Society for Microbiology, Washington, DC 20005.	
		McMURRAY, DAVID N., "Guinea Pig Model of Tuberculosis". Chapter 9, p. 135-147. *Tuberculosis: Pathogenesis, Protection and Control*, Barry R. Bloom (ed.), 1994, American Society for Microbiology, Washington, DC 20005.	
		DANNENBERG, JR., ARTHUR M., "Rabbit Model of Tuberculosis". Chapter 10, p. 149-156. *Tuberculosis: Pathogenesis, Protection and Control*, Barry R. Bloom (ed.), 1994, American Society for Microbiology, Washington, DC 20005.	
		THOEN, CHARLES O. "Tuberculosis in Wild and Domestic Mammals". Chapter 11, p. 157-162. *Tuberculosis: Pathogenesis, Protection and Control*, Barry R. Bloom (ed.), 1994, American Society for Microbiology, Washington, DC 20005.	
		JACOBS, JR., WILLIAM R. "*Mycobacterium tuberculosis*: A Once Genetically Intractable Organism", p. 1-16, *Molecular Genetics of Mycobacteria*, G.F. Hatful and W.R. Jacobs, Jr., (eds.)., 2000, ASM Press, Washington, D.C.	
JR		BARLETTA, RAUL G. , et al. "Vaccines Against Intracellular Pathogens", *Subcellular Biochemistry*. 2000, Vol. 33, p. 559-599.	

Examiner Signature		Date Considered	10/11/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number:	10/738,938
Filing Date:	December 17, 2003
First Named Inventor:	Raul G. Barletta
Group Art Unit:	1652
Examiner Name:	~~Not Yet Assigned~~ RAMIREZ, DELIA
Attorney Docket Number:	801204-0003

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	10/11/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number:	10/738,938
Filing Date:	December 17, 2003
First Named Inventor:	Raul G. Barletta
Group Art Unit:	1652
Examiner Name:	~~Not Yet Assigned~~ RAMIREZ, DELIA
Attorney Docket Number:	801204-0003

OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS AND INFORMATION

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
DL		FENG, ZHENGYU, and Barletta, Raúl, "Roles of *Mycobacterium smegmatis* D-Alanine:D-Alanine Ligase and D-Alanine Racemase in the Mechanisms of Action of and Resistance to the Peptidoglycan Inhibitor D-Cycloserine", *Antimicrobial Agents and Chemotherapy*. 2003, Vol. 47, No. 1, p. 283-291.	
		CHACON, OFELIA, et al., "*Mycobacterium smegmatis* D-Alanine Racemase Mutants Are Not Dependent on D-Alanine for Growth", *Antimicrobial Agents and Chemotherapy*. 2002, Vol. 46, No. 1, p. 47-54.	
		CÁCERES, NANCY E., et. al., "Overexpression of the D-Alanine Racemase Gene Confers Resistance to D-Cycloserine in *Mycobacterium smegmatis*", *Journal of Bacteriology*. Aug. 1997, Vol. 179, No. 16, p. 5046-5055.	
		ZHENGYU, FENG, et. al., "*Mycobacterium smegmatis* L-Alanine Dehydrogenase (Ald) Is Required for Proficient Utilization of Alanine as a Sole Nitrogen Source and Sustained Anaerobic Growth", *Journal of Bacteriology*. Sept. 2002, Vol. 184, No. 18, p. 5001-5010.	
		KAMOGASHIRA, TAKASHI and Takegata, Setsuko, "A Screening Method for Cell Wall Inhibitors Using a D-Cycloserine Hypersensitive Mutant", *The Journal of Antibiotics*. June 1988, Vol. XLI, No. 6, p. 803-806.	
		STRYCH, ULRICH, et. al., "Characterization of the Alanine Racemases from Two Mycobacteria", *FEMS Microbiology Letters*. 2001, Vol. 196, p. 93-98.	
		COPIÉ, VALÉRIE, et al., "Inhibition of Alanine Racemase by Alanine Phosphonate: Detection of an Imine Linkage to Pyridoxal 5' –Phosphate in the Enzyme-Inhibitor Complex by Solid-State ^{15}N Nuclear Magnetic Resonance". *Biochemistry*, 1988, Vol. 27, p. 4966-4970.	
		HEATON, MICHAEL P., et. al, "Controlled Lysis of Bacterial Cells Utilizing Mutants with Defective Synthesis of D-Alanine", *Can. J. Microbiol.*, 1988, Vol. 34, p. 256-261.	
		PATCHETT, ARTHUR A., et. al., "Antibacterial Activities of Fluorovinyl- and Chlorovinylglycine and Several Derived Dipeptides", *Antimicrobial Agents and Chemotherapy*. Mar. 1988, Vol. 32, No. 3, p. 319-323.	
		LAMBERT, MARY P., and Neuhaus, Francis C., "Mechanism of D-Cycloserine Action: Alanine Racemase from Escherichia coli W", *Journal of Bacteriology*. 1972, Vol. 110, No. 3, p. 978-987.	
		HOLS, PAXCAL, et. al, "Conversion of *Lactococcus Lactis* from Homolactic to Homoalanine Fermentation through Metabolic Engineering", *Nature Biotechnology*. June 1999, Vol. 17, p. 588-592.	
		TAUCH, ANDREAS, et. al., "The Alanine Racemase Gene *alr* is an Alternative to Antibiotic Resistance Genes in Cloning Systems for Industrial *Corynebacterium Glutamicum* Strains", *Journal of Biotechnology*. 2002, Vol. 99, p. 79-91.	
		ARIAS, CESAR A., et. al, "Serine and Alanine Racemase Activities of VanT: a Protein Necessary for Vancomycin Resistance in *Enterococcus Gallinarum* BM4174", *Microbiology*. 2000, Vol. 146, p. 1727-1734.	
DL		THOMPSON, ROBERT J., et. al, "Pathogenicity and Immunogenicity of a *Listeria monocytogenes* Strain That Requires D-Alanine for Growth", *Infection and Immunity*. Aug. 1998, Vol. 66, No.8, p. 3552-3561.	

10/11/06

Appl. No 10/738938
Inventor : Barletta et al.
Examiner : Ramirez, Delia

		HOLS, P., et. al., "The Alanine Racemase Gene is Essential for Growth of *Lactobacillus plantarum*", *Journal of Bacteriology*. June 1997, Vol. 179, No. 11, p. 3804-3807.	
		NEIDHART, DAVID J., et. al., "X-ray Crystallographic Studies of the Alanine-specific Racemase from *Bacillus stearothermophilus*", *The Journal of Biological Chemistry*. 1987, Vol. 262, No. 32, p. 15323-15326.	
		BRAUNSTEIN, MIRIAM, et. al., "Genetic Methods for Deciphering Virulence Determinants of *Mycobacterium tuberculosis*", *Virulence and Essential Gene Identification*. 2002 p. 67-99.	
		TYAGI, JAYA S. and Sharma, Deepak, "*Mycobacterium smegmatis* and Tuberculosis", *TRENDS in Microbiology*. February 2002, Vol. 10, No. 2, p. 68-69.	
		DAVID, HUGO L., et. al., "Susceptibility of Mycobacterial D-Alanyl-D-Alanine Synthetase to D-Cycloserine", *American Review of Respiratory Disease*. 1969, Vol. 100, p. 579-581.	
		NEUHAUS, FRANCIS C. "The Enzymatic Synthesis of D-Alanyl-D-alanine. I. Purification and Properties of D-Alanyl-D-Alanine Synthetase", *Journal of Biological Chemistry*. March 1962, Vol. 237, No. 3, p. 778-786.	
		PETEROY, MARCY, et. al., "Characterization of a *Mycobacterium smegmatic* Mutant That Is Simultaneously Resistant to D-Cycloserine and Vancomycin", *Antimicrobial Agents and Chemotherapy*. June 2000, Vol. 44, No. 6, p. 1701-1704.	
		MANNING, JAMES M., et. al., "Inhibition of Bacterial Growth by β-Chloro-D-Alanine", *Proc. Nat. Acad. Sci.* February 1974, Vol. 71, No. 2, p. 417-421.	
		DAVID, SUZANA, "Synergic Activity of D-Cycloserine and β-Chloro-D-Alanine Against *Mycobacterium tuberculosis*", Journal of Antimicrobial Chemotherapy. 2001, Vol. 47, p. 203-206.	
		MARSHALL, C. GARY and Wright, Gerard D., "Ddl1N from Vancomycin-Producing *Amycolatopsis orientalis* C329.2 Is a VanA Homologue with D-Alanyl-D-Lactate Ligase Activity", *Journal of Bacteriology*. Nov. 1998, Vol. 180, No. 21, p. 5792-5795.	
		RASTOGI, NALIN, et. al., "Enhancement of Drug Susceptibility of *Mycobacterium avium* by Inhibitors of Cell Envelope Synthesis", *Antimicrobial Agents and Chemotherapy*. May 1990, Vol. 34, No. 5, p. 759-764.	
		DUTKA-MALEN, SYLVIE, et. al., "Sequence of the vanC Gene of *Enterococcus gallinarum* BM4174 encoding a D-Alanine:D-Alanine Ligase-Related Protein Necessary for Vancomycin Resistance", *Gene*. 1992, Vol. 112, p. 53-58.	
		BELANGER, AIMEE E. and Inamine, Julia M., "Genetics of Cell Wall Biosynthesis", *Molecular Genetics of Mycobacteria*. Hatfull, G.F. and Jacobs, W.R. (Eds.), ASM Press, Washington, D.C., 2000, p. 191-202.	
		REITZ, RICHARD H., et. al., "The Biochemical Mechanisms of Resistance by Streptococci to the Antibiotics D-Cycloserine and O-Carbamyl-D-Serine", *Biochemistry*. Aug. 1967, Vol. 6, No. 8, p. 2561-2570.	
		WALSH, CHRISTOPER T., "Enzymes in the D-Alanine Branch of Bacterial Cell Wall Peptidoglycan Assembly", *Journal of Biological Chemistry*. 1989, Vol. 264, No. 5, p. 2393-2396.	
		DAVID, HUGO L., "Resistance to D-Cycloserine in the Tubercle Bacilli: Mutation Rate and Transport of Alanine in Parental Cells and Drug-Resistant Mutants", *Applied Microbiology*. May 1971, Vol;. 21, No. 5, p. 888-892..	
		ZYGMUNT, WALTER A., "Antagonism of D-Cycloserine Inhibition of Mycobacterial Growth By D-Alanine", *J. Bacteriol.* 1963, Vol. 85, p. 1217-1220.	
		YEW, WING WAI, et. al., "Adverse Neurological Reactions in Patients with Multidrug-Resistant Pulmonary Tuberculosis After Coadministration of Cycloserine and Ofloxacin", *Clinical Infectious Diseases*. August 1993, Vol. 17, 288-289.	

10/11/06

Appl. No : 10/738 938
Inventor : Barletta et al.
Examiner : Ramirez, Delia

DR		KAUFMAN, DARRELL and Manley, William F., "A New Procedure for Determining DL Amino Acid Ratios in Fossels Using Reverse Phase Liquid Chromatography", 1998. *Quaternary Geochronology*, Vol. 17, p. 987-1000.	
DR		NEUHAUS, FRANCIS C., "D-Cycloserine and O-Carbamyl-D-serine", *Antibiotics - Vol. 1, Mechanism of Action.* Gottlieb, D and Shaw, Paul D. (eds.), Springer-Verlag New YorK Inc., 1967, p. 40-83.	

Examiner Signature		Date Considered	10/11/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.